Document:

EX-10.23

 Exhibit 10.23 
 AMENDMENT AND CONSENT 
 THIS AMENDMENT AND CONSENT (the
“Amendment and Consent”) is made and entered into as of April 10, 2013, by and among Marrone Bio Innovations, Inc., a Delaware corporation (the “Company”), and Gordon Snyder, an individual, as administrative
agent for the Lenders (as defined below) (the “Agent”). 
 WHEREAS, the Company, the Agent and
certain of the Lenders (as defined therein) are parties to that certain Loan Agreement dated as of October 2, 2012 (the “Deal A Loan Agreement”), related Security Agreements (as defined in the Deal A Loan Agreement) and other
agreements and documents (collectively, including the Deal A Loan Agreement and the Security Agreements, the “Deal A Loan Documents”). 
 WHEREAS, the Company, the Agent and certain of the Lenders (as defined therein) are parties to that certain Loan Agreement dated as of October 16, 2012 (the “Deal B Loan
Agreement”), related Security Agreement (as defined in the Deal B Loan Agreement) and other agreements and documents (collectively, including the Deal B Loan Agreement and the Security Agreement, the “Deal B Loan
Documents”). 
 WHEREAS, the Company and the Agent (on behalf of the Lenders) are parties to that
certain Intercreditor Agreement dated as of December 6, 2012, with Syngenta Ventures Pte. Ltd. (the “Intercreditor Agreement”). 
 WHEREAS, the parties to the Deal A Loan Documents wish to amend the same in order to increase the amount of the Loan (as defined in the Deal A Loan Agreement) by up to an additional
US$5,000,000 by making certain additional advances to the Company, changing certain terms and as otherwise set forth below; 

WHEREAS, the parties to the Deal B Loan Documents wish to amend the same to convert a portion of the outstanding balance
of the Loan (as defined in the Deal B Loan Agreement) into an additional advance under the Deal A Loan Documents and, concomitantly, to reduce the balance of the Loan evidenced and secured by the Deal B Loan documents by an amount equal to the
principal amount of the portion so converted to an additional advance under the Deal A Loan Documents. 

WHEREAS, the Company and the Agent have the full right, power and authority to amend the terms of the Deal A Loan
Documents and the Deal B Loan Documents and, respectively, to bind the Company and the Lenders thereto. 
 NOW,
THEREFORE, in consideration of these premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree: 

 

	1.	Definitions. 

 Capitalized
terms used herein without definition shall have the meanings ascribed to them in the Deal A Loan Documents and the Deal B Loan Documents. 

  
 1. 

	2.	Loan Amount; Additional Advances; Partial Conversion; Notes. 

 2.1 Section 2.01 of the Deal A Loan Agreement is hereby amended by deleting the term “$7,500,000” in the text thereof and substituting in its stead the term “$12,500,000.”

 2.2 Certain of the Lenders named along with their Commitment amounts on Schedule 1 (Commitments and Pro Rata Shares)
attached to the Deal A Loan Agreement and at least one other party which is not currently a Lender under the Deal A Loan Documents but is a related party to the named Lenders thereon, wish to make additional cash advances of funds to the Company
(“Additional Advances”) in the respective amounts shown on the First Amended Deal A Schedule 1 attached hereto and by this reference made a part of this Amendment and Consent. The attached First Amended Deal A Schedule 1
hereby supplements and replaces for all purposes Schedule 1 attached to the Deal A Loan Agreement to the extent the Lenders named therein make the specified advances. Such additional advances may be made by wire of immediately available
funds to the Company. Such additional advances shall be subordinate in priority of payment and security interests to the priority in payment and security interests of the Lenders making the initial advances under the Deal A Loan Documents as shown
on the First Amended Deal A Schedule 1. 
 2.3 The sole Lender under the Deal B Loan Documents wishes: (a) to
convert a portion of the outstanding principal balance, plus interest accrued to date on such converted portion, of the Loan evidenced by that certain outstanding Note issued pursuant to the Deal B Loan Agreement (“Deal B Note”),
into an additional advance under the Deal A Loan Documents as amended by this Amendment and Consent; and (b) to receive an amended and restated Note (“Amended and Restated Deal B Note”) evidencing the Company’s
indebtedness under the Deal B Loan Documents for the remaining, unconverted portion of the principal Loan balance plus interest accrued to date under the Deal B Note, such Amended and Restated Deal B Note to be in the principal amount of the Deal B
Note LESS the amount of the Deal B Note which is converted to an additional advance under the Deal A Loan Documents, all as set forth on the First Amended Deal A Schedule 1 and on the First Amended Deal B Schedule 1 attached hereto.
The attached First Amended Deal B Schedule 1 hereby supplements and replaces for all purposes Schedule 1 attached to the Deal B Loan Agreement. Agent, on behalf of the sole Lender under the Deal B Loan Agreement, hereby agrees that the
conversion of a portion of the Loan under the Deal B Loan Agreement evidenced by the Deal B Note into a Note evidencing an additional advance under the Deal A Loan Agreement as contemplated hereby and in accordance with the terms hereof shall be
deemed paid without penalty or payment notwithstanding any limitations on prepayment (including notice requirements) under the Deal B Loan Agreement or otherwise. 
 2.4 If and to the extent that individuals or entities shall make additional advances to the Company pursuant to the Deal A Loan Agreement as amended by this Amendment and Consent on or after the date of
this Amendment and Consent, each and every such individual or entity shall become a party to the Deal A Loan Documents for all purposes (including representations and warranties), be deemed a “Lender” and a party thereunder and shall
execute and deliver counterpart signature pages to the Deal A Loan Documents, and the Company shall execute and deliver to each such Lender of an additional advance a Note in substantially the same form as the Notes issued in connection with the
Deal A Loan Documents, each in the principal amount of such additional advance made by such Lender, respectively. 
  

	3.	Warrants. 

 If and to the
extent that individuals or entities named as Lenders on the First Amended Deal A Schedule 1 shall make Loans to the Company in the form of additional advances pursuant to the Deal A Loan Agreement, as amended by this Amendment and Consent, on
or after the date of this Amendment 

  
 2. 

 
and Consent, the Company shall issue a warrant to any such individual or entity substantially in the form attached as Exhibit A to the Deal A Loan Agreement. Provided, however,
notwithstanding the foregoing and any other provision of the Deal A Loan Documents, each such warrant issued to a Lender making an additional advance as anticipated hereby (and without limitation or amendment to any warrants previously issued
pursuant to the Deal A Loan Documents prior the date of this Amendment and Consent, the terms of which previously issued warrants shall remain unchanged by this Amendment and Consent) shall only be exercisable eighteen (18) months after the
closing of the Company’s IPO or a Sale of the Company for the purchase of that number of shares of common stock of the Company as is equal to 20% of the original principal amount of such Lender’s Loan divided by 70% of the value of such
common stock in the Company IPO or such Sale of the Company, as applicable. The exercise price for shares purchased under the warrants shall be equal to 70% of the value of such common stock in the Company IPO or such Sale of the Company, as
applicable. 
  

	4.	Interest. 

Section 2.04 of the Deal A Loan Agreement is hereby amended by adding the following sentence to the end of the text thereof:

 “Provided, however, notwithstanding the foregoing, any Lender may, at its request (which request shall be communicated in
writing by Lender (or the Agent on such Lender’s behalf) to the Company), defer all interest due hereunder, in which case such interest shall accrue and be paid on the Applicable Maturity Date.” 

 

	5.	Prepayment. 

Section 2.09(a) of the Deal A Loan Agreement is hereby amended by deleting the text thereof and substituting in its stead the
following text: 
 Optional Prepayments. Prior to the Initial Maturity Date, the Company may prepay the outstanding amount of the
Loans, either (i) with the written consent of the Lenders (or the Agent on such Lenders’ behalf), or (ii) without such consent but with the additional payment of an amount equal to such interest that would be payable (but for such
prepayment) from the date of such prepayment until the Initial Maturity Date (“Additional Prepayment Compensation”). 
 For the
avoidance of doubt, the foregoing language providing for Additional Prepayment Compensation replaces, supersedes and substitutes entirely for the provision in Section 2.09 (a) of the Deal A Loan Agreement limiting the rights of Borrower to
prepay the Deal A Loan until earliest of (i) the date that is six months after the Closing Date, (ii) the closing of the Company IPO, and (iii) the date on which a Sale of the Company is consummated. 

 

	6.	Consent. 

 Anything to the
contrary in the Deal A Loan Documents, the Deal B Loan Documents or the Intercreditor Agreement notwithstanding, the Company and the Agent (on behalf of all of the Lenders) consent to (a) the incurrence of additional indebtedness by the Company
pursuant to the Deal A Loan Documents as amended and as contemplated herein; (b) the conversion of a portion of the Deal B Note and issuance of the Amended and Restated Deal B Note as contemplated herein; (c) the continuing subordination
as specified in the Intercreditor Agreement of the indebtedness and security interests evidenced and secured under the Deal B Loan Documents to interests of all the Lenders under the Deal A Loan Documents, including the Lenders making additional
advances in accordance with this Amendment 

  
 3. 

 
and Consent and the concomitant increase in the amount of indebtedness evidenced and secured under the Deal A Loan Documents; and (d) any and all security interests and liens granted in
connection with the incurrence of indebtedness by Company as a result of such additional advances. 
  

	7.	General. 

 The term
“Agreement” as used in the Deal A Loan Agreement and the Deal B Loan Agreement shall for all purposes refer to the Deal A Loan Agreement and the Deal B Loan Agreements as respectively amended by this Amendment and Consent. Except to the
extent expressly revised by the terms of this Amendment and Consent, all the terms and conditions of the Deal A Loan Documents and the Deal B Loan Documents remain in full force and effect. From and after the date of this Amendment and Consent, upon
the request of the Agent or the Company, the Company and the Agent (on behalf of the Lenders) shall execute and deliver such instruments, documents or other writings as may be reasonably necessary or desirable to confirm and carry out and to
effectuate fully the intent and purposes of this Amendment and Consent. This Amendment and Consent shall be governed by and construed under the laws of the State of California without reference to the choice of law provisions thereof. This Amendment
and Consent may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Amendment and Consent may be executed and delivered by facsimile and
upon such delivery the facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other parties. The Company agrees to pay on demand the reasonable fees and disbursements of one special
counsel for the Lenders in connection with the negotiation, preparation, execution, and delivery of this Amendment and Consent and any related documents in an amount not to exceed $5,000; provided that in no event shall the Agent or any Lender
deduct such fees and disbursements of counsel from the Loans and Agent shall promptly provide the Company with a detailed invoice of such fees and disbursements of counsel upon request thereof. 

[Remainder of page intentionally left blank] 

  
 4. 

 IN WITNESS WHEREOF, the parties hereto
have executed this Amendment and Consent as of the date set forth in the first paragraph hereof. 
  

							
	COMPANY:	 		 	AGENT:
			
	 MARRONE BIO INNOVATIONS, INC.,

a Delaware corporation
	 		 	GORDON SNYDER
				
	By:	 	/s/ Pam Marrone	 		 	/s/ Gordon Snyder
		 	 Pam Marrone

President
	 		 	

 Signature Page to Amendment and Consent 

 FIRST AMENDED DEAL A SCHEDULE 1 

 

					
	 Lender
	 	Commitment Amount
(payment 
method)	 
	 Dan and Danna Holmes Charitable Remainder Trust I
	 	$	550,000 	(cash) 
	 Dan and Danna Holmes Charitable Remainder Trust II
	 	$	450,000 	(cash) 
	 Lorna Pomeroy
	 	$	1,000,000 	(cash) 
	 Cindy Evans
	 	$	800,000 	(cash) 
	 Cindy Evans Charitable Remainder Trust
	 	$	300,000 	(cash) 
	 Lina Tans
	 	$	1,000,000 	(cash) 
	 Anne Berndt 2012 Grandchildren’s Trust UAD 10/01/12 Anne Berndt TTEE
	 	$	750,000 	(cash) 
	 Kevin Frank
	 	$	200,000 	(cash) 
	 John and Wendy Evans Revocable Trust
	 	$	770,000 	(cash) 
	 John and Wendy Evans Charitable Remainder Trust I
	 	$	400,000 	(cash) 
	 John and Wendy Evans Charitable Remainder Trust II
	 	$	600,000 	(cash) 
	 Jane Blair Vilas Revocable Trust
	 	$	680,000 	(cash) 
	 Subtotal
	 	$	7,500,000	  
	 On or after April 10, 2013
	 			
		
	ADDITIONAL	 	ADVANCES	 
	 Dan and Danna Holmes Charitable Remainder Trust I
	 	$	100,000 	(cash) 
	 Dan and Danna Holmes Charitable Remainder Trust II
	 	$	200,000 	(cash) 
	 Dan and Danna Holmes 2004 Revocable Trust
	 	$	200,000 	(cash) 
	 Cindy Evans
	 	$	200,000 	(cash) 
	 Cindy Evans Charitable Remainder Trust
	 	$	300,000 	(cash) 

					
	 John and Wendy Evans Charitable Remainder Trust II
	  	$	200,000 	(cash) 
	 Jane Blair Vilas Revocable Trust
	  	$	500,000 	(cash) 
	 Evans Family Limited Partnership
	  	$	500,000 	(cash) 
	 Irrevocable Trust U/W J.H. Evans
	  	$	1,500,000 	(cash) 
	 Irrevocable Trust U/W J.H. Evans
	  	$
  
  
	1,250,000

(Partial Deal B
 Note Conversion
	 
  

) 

	 Subtotal
	  	$	4,950,000	  
	 Total
	  	$	12,450,000	  

 FIRST AMENDED DEAL B SCHEDULE 1 

 

					
	 Lender
	  	 Commitment Amount
	 
	 Irrevocable Trust U/W J.H. EVANS
	  	$	1,250,000	* 
	 Total
	  	$	1,250,000	  

  

	*	Note that the additional principal amount of $1,250,000 of the Loan was converted on April 10, 2013 (the “Conversion Date”) into a Note under the
October 2, 2012 Loan Agreement, but accrued and unpaid interest on this additional principal amount from the date of the Loan to the Conversion Date, and on such unpaid interest from the Conversion Date, shall be accrued and paid on the
Applicable Maturity Date as provided in the Agreement.EX-10.24

 Exhibit 10.24 

LICENSE AGREEMENT 

THIS LICENSE AGREEMENT (this “Agreement”) is made as of
May 22, 2007 (the “Effective Date”), between KHH BIOSCI, INC., a North Carolina corporation, having its principal office at 634 Lake Hogan Lane, North Carolina 27516 United
States of America (“KHH”) and MARRONE ORGANIC INNOVATIONS, INC., a Delaware corporation, having its principal office at 215 Madson Place, Suite B, Davis, California
95618, United States of America (“MOI”). 
 ARTICLE 1 

BACKGROUND 

1.1    KHH has conducted research on the extract of Reynoutria sachalinensis and formulations that include
this extract and owns a license and various intellectual property rights associated with such extract. KHH is interested in sub-licensing such rights to MOI for further commercial development and marketing. 

1.2    MOI is in the business of research, development, registration and commercialization of natural products as
biopesticides. MOI is interested in assessing the above described on such extract and related rights of KHH, which MOI may develop, register and bring to market. 

1.3    To advance these goals, MOI and KHH have determined to enter into a commercial relationship regarding the
future development, registration, commercialization, sales and marketing of products based on such extract and related rights. 
 ARTICLE
2 
 DEFINITIONS 

2.1    “Affiliate” means, in relation to a party to this Agreement, a body corporate which from
time to time is, directly or indirectly, controlled by, in control of, or under common control with, such party and, for these purposes, “control” shall consist of the ownership of over 50% of the voting stock of the applicable entity.

 2.2    “Agro-Kanesho Assignment and License Agreement” means that Assignment and License Agreement
between KHH and Agro-Kanesho Co., Ltd., a Japanese corporation dated 18 September 2000, attached as Exhibit A. 

2.3    “BASF” means BASF Aktiengesellschaft. 

2.4    “BASF Agreement” means the Assignment and License Agreement between KHH and BASF, executed
April 20, 1998. 
 2.5    “BASF Technology Rights” means the technology rights, including
TECHNICAL INFORMATION, as set forth in the BASF Agreement. Attached as Exhibit B. 
 2.6    “BASF
Territory” means the Territory as defined in the BASF Agreement. 

 2.7    “Confidential Information” means, as to either
party and without limitation, such party’s proprietary or confidential data, know-how, formulas, compositions, processes, documents, designs, sketches, photographs, plans, graphs, drawings, specifications, equipment, samples, reports, findings,
inventions, ideas and information, including business information related to Products and the BASF Technology Rights and the KHH Technology Rights. 

2.8    “Customer” means any purchaser of a Product other than KHH, MOI, an Affiliate or a
Sublicensee. 
 2.9    “Deductible Expenses” means the following items of expense incurred in
connection with Sales of Products to the extent paid or allowed by MOI or a Sublicensee, and included in accordance with recognized principles of accounting in the gross sales price billed: (a) sales, use or turnover taxes; (b) excise,
value added, importation or other taxes, custom duties or consular fees; (c) transportation, freight, and handling charges, and insurance on shipments to customers; (d) trade, cash or quantity discounts or rebates to the extent actually
granted (including government-mandated rebates); (e) rebates, refunds, and credits for any rejected or returned Products or due to billing errors or because of retroactive price reductions, rebates or chargebacks; (f) uncollected accounts
receivable attributable to Sales of Products; and (g) sales related fees or commissions paid for efforts in arranging actual Sales of Products. 

2.10    “Exclusive” means that for the term of this Agreement KHH will not use or license to any
licensee, other than MOI, the Licensed Patents, the BASF Technology Rights, the Technology Rights, subject to the rights of BASF to “Technical Information” (as defined in the BASF Agreement) under Section 3.3 of the BASF Agreement,
and subject to the Agro-Kanesho Assignment and License Agreement. 
 2.11    “Licensed Patents”
means: (i) all domestic and foreign patents and patent applications listed in Exhibit C attached hereto; (iii) all divisionals, continuations, and continuations-in-part of such patents and patent applications; (iv) all patents
that issue on any of the foregoing patent applications; (v) all foreign counterparts of the foregoing patents and patent applications; and (vi) all reissues, reexaminations, renewals, extensions, and supplementary protection certificates
relating to any of the foregoing patents. Exhibit C may be updated from time to time on mutual agreement. 

2.12    “Licensed Patent Rights” means any and all rights under the Licensed Patents. 

2.13    “Net Revenues” means the amount received by MOI or a Sublicensee, in each case for the
Sale of a Product to a Customer, less the Deductible Expenses applicable to such Sale. Net revenues shall also include imputed Net Revenues as provided in Section 10.4. 

2.14    “Product” means any product or device that is covered by, or is made by or utilizes a
process or material covered by, any Valid Claim or which utilizes any BASF Technology Rights or KHH Technology Rights. 

2.15    “Registration” means approval by the United States Environmental Protection Agency of a
microbial, a substance or a mixture of substances, as a biochemical or microbial pesticide. 

 2.16    “Sale” means the sale, transfer, exchange or
other commercial disposition of a Product. In case of doubt, Sales of Products will be deemed consummated no later than receipt of payment by a Customer for the applicable transaction involving such Product. 

2.17    “Sublicensee” will mean, with respect to a particular Product, a third party to which MOI has
granted a license or sublicense under any or all of the Licensed Patent Rights. 
 2.18    “KHH Technology
Rights” means any and all ideas, inventions, formulae, processes, trade secrets and substantial know-how, intellectual property, techniques, methods, specifications, practices, data and other forms of information relating to the processes,
methods and techniques for manufacturing, formulating and using the Licensed Patent Rights or relating to the Products, whether patentable or not and whether or not reduced to practice, including Licensed Patent Rights and registration data in each
case owned or licensable by KHH or directly or indirectly derived from the foregoing or from Confidential Information of Licensor at any time during the term of this Agreement, other than BASF Technology Rights. 

2.19    “Technology Rights” means KHH Technology Rights and BASF Technology Rights. 

2.20    “Territory” means: 

a) with respect to the Licensed Patents, the United States of America 

b) with respect to the BASF Technology Rights, the BASF Territory 

c) with respect to the KHH Technology Rights, the world. 

2.21    “Trademark” means all right of KHH to the trademark Milsana® as well as any unregistered version thereof, and associated goodwill. 

2.22    “Valid Claim” means, with respect to any country, a claim of an issued patent within the Licensed
Patents that has not, with respect to such country (a) expired or been canceled, (b) been declared invalid by an unreversed decision of a court or other appropriate body of competent jurisdiction from which there can be no further appeal,
(c) been admitted to be invalid or unenforceable through reexamination, reissue, disclaimer or otherwise, and/or (d) been abandoned in accordance with or as permitted by the terms of this Agreement or by mutual written agreement. 

ARTICLE 3 

REPRESENTATIONS, WARRANTIES AND COVENANTS OF KHH 

KHH hereby represents, warrants and covenants to MOI as follows: 

3.1    Corporate Power and Authority.  KHH has the corporate power and authority to execute and
deliver this Agreement and perform its obligations hereunder. KHH also represents and warrants that, except as set forth in Exhibit C, it has the right and the authority, including ownership or appropriate and valid licenses, to grant the licenses
set forth in Article 5 and to grant and perform its other rights and obligations hereunder. 

 3.2    Compliance with Law. KHH will conduct its activities and
operations in material compliance with all applicable laws, statutes, rules or regulations. 
 3.3    No
Conflicting Agreement.  KHH represents and warrants that it has not granted to any third party any right or interest in any of the Licensed Patent Rights or other Technology Rights that is inconsistent with the rights granted to MOI
herein and will not grant any third party such a right during the term of this Agreement. 
 3.4    No
Litigation.  KHH represents and warrants that, as of the date of execution of this Agreement, there are no pending or, to its actual knowledge, threatened actions, suits, investigations, claims, or proceedings in any way relating to
the Licensed Patent Rights or other Technology Rights. 
 3.5    BASF Agreement.  KHH represents
and warrants that this Agreement is consistent with the relevant terms of the BASF Agreement and that MOI has no direct obligation to BASF under the BASF Agreement. As between KHH and MOI, KHH is solely responsible for performing its obligations
under the BASF Agreement. 
 ARTICLE 4 

REPRESENTATIONS, WARRANTIES AND COVENANTS OF MOI 

MOI represents, warrants and covenants the following to KHH: 

4.1 Corporate Power and Authority.  MOI has the corporate power and authority to execute and deliver this Agreement
and perform its obligations hereunder and thereunder. 
 4.2 Compliance with Law.  MOI will conduct its activities
and operations in material compliance with all applicable laws, statutes, rules or regulations. 
 ARTICLE 5 

LICENSE GRANT AND APPLICATION ASSIGNMENT 

5.1    Grant.  Subject to the terms and conditions of this Agreement, to the terms and conditions
of the BASF Agreement, to the terms and conditions of the Agro-Kanesho Assignment and License Agreement. KHH hereby grants to MOI an Exclusive, royalty-bearing, sublicensable license under the Licensed Patent Rights, BASF Technology Rights and KHH
Technology Rights; and Trademarks, to research, develop, make, have made, import, have imported, use, have used, sell, have sold, offer for sale, have offered for sale, and otherwise exploit Products in the Territory. 

5.2    Limits on Sublicensing.  MOI has the right to grant nonexclusive or exclusive sublicenses
hereunder, provided, that: (a) MOI will include all Net Revenues of Sublicensees in MOI’s reports to KHH, as provided in Section 7.1, and MOI will pay royalties thereon to KHH calculated pursuant to
Section 6.2; and (b) MOI may grant sublicenses of no greater scope than the licenses granted under Section 5.1. 

5.3    Assignment of Sublicenses.  Any sublicenses granted by MOI of the rights it receives
under Section 5.1, including any nonexclusive sublicenses, will remain in effect and, at 

 
MOI’s and KHH’s election, may be assigned to KHH if the license in Section 5.1 terminates pursuant to Article 13, provided the financial obligations of each
Sublicensee to KHH will be at least the same as the Sublicensees’ obligations to MOI with respect to Licensed Patent Rights but, in any event, will not be less than MOI’s obligations to KHH for such sublicenses under this Agreement. In
such event and subject to the preceding sentence, KHH will assume all the rights and obligations of MOI under such sublicenses with respect to the licenses granted under the Licensed Patents Rights and other Technology Rights to such Sublicensees.
In the event of such assignment, unless otherwise agreed by KHH, KHH will not be obligated to assume any obligation of MOI under the license agreement other than the granting of the license rights consistent with the terms hereof. 

5.4    Term of License.  The license grant in Section 5.1 will continue for the term
of this Agreement as set forth in Section 13.1, unless the Agreement is earlier terminated in accordance with Article 13 or otherwise. 

ARTICLE 6 
 ROYALTIES

 6.1    License Fee.  In consideration for the license rights granted herein, MOI will pay
KHH a license fee of [*****] for the licenses granted under this Agreement. Such license fee is payable as follows: 

(a)    [*****] of such fee is due within 15 days after the execution of this Agreement; 

(b)    [*****] of such fee is due within 15 days after satisfactory completion by KHH of the Diligence (as defined
in Section 8.3); provided that, unless this Agreement is sooner terminated, such fee is payable within 60 days of the Effective Date; and 

(c)    [*****] be paid within 75 days of the Effective Date, contingent on successful due diligence. 

6.2    Royalty on Sales of Products; Exclusions.  With respect to the Sale of Products by or for
MOI, and Affiliate of MOI, a Sublicensee, or and Affiliate of a Sublicensee, MOI will pay KHH [*****] of Net Revenues based on such Sale in such country. No more than one royalty payment will be due with respect to a Sale of a particular Product. No
multiple royalties will be payable because any Product, or its manufacture, sale or use is covered by more than one Valid Claim in a given country. No royalty will be payable under this Section with respect to (a) Sales of Products among MOI,
its Sublicensees or Affiliates, provided that the Sublicensees or Affiliates are not end users of the Product, or (b) Products distributed for use in research and/or development or as promotional samples or otherwise distributed without charge
to Third Parties. 
 6.3    Maximum Amount; Duration of Royalty Obligation.  Notwithstanding any
other term of this Agreement, MOI is not obligated to pay KHH any royalties, license fees or other amounts under this Article or Article 10, including royalties based on MOI or Sublicensee Product Sales, in excess of [*****] (the
“Maximum Amount”). Subject to the immediately preceding sentence, royalties due under this Article will be payable in U.S. Dollars on a country-by-country and Product-by-Product basis until the expiration of the Term of this
Agreement. 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

 6.4    Minimum Royalties.  If MOI pays to KHH,
royalties, service fees and other amounts, pursuant to this Article or Article 10, in calendar years 2007, 2008 and 2009, less than [*****] then within 30 days of the end of such year MOI must pay KHH such shortfall. MOI will be entitled
to credit the amount of any payment of the shortfall made under this Section against any future actual royalty amounts owed pursuant to Section 6.2 or 10.4. 

6.5    Expenses.  Independent of the foregoing royalty obligations, MOI shall be responsible for payment
of all reasonable and pre-approved expenses of KHH in fulfilling its obligations to MOI under this Agreement. 
 ARTICLE 7 

REPORTS, PAYMENTS AND RECORD 

7.1    Reports; Payment.  Following the first Sale of a Product, on or before the 30th day after the end of each MOI fiscal quarter, and for so long as royalties are payable under this Agreement, MOI will render to KHH a report in writing, setting forth Net Revenues and the number of
units of Products Sold in each country during such quarter by MOI and Sublicensees. MOI will pay to KHH with each such report any royalties due to KHH as indicated in such report. 

7.2    Currency Exchange; Overdue Interest.  Net Revenues received by MOI from Sublicensees in
currencies other than U.S. dollars will be converted into U.S. dollars according to MOI’s reasonable standard internal conversion procedures. Overdue payments under this Agreement will bear interest from the date due until paid at the lower of
a per annum rate 1% above the prime rate in effect as published in the Wall Street Journal or at the highest interest rate permissible under applicable law. 

7.3    Records; Audit.  MOI will keep complete and accurate records and books of account in
respect of all Products made and sold by MOI, its Affiliates and Sublicensees, under this Agreement, and, of all payment obligations to KHH under this Agreement. KHH will have the right, during business hours, no more often than annually unless
there is breach of this Agreement by MOI to engage a nationally-certified auditing firm reasonably acceptable to MOI to examine such records and books of MOI its Sublicensees and Affiliates to verify the amounts paid to KHH hereunder. MOI will keep
the same for at least 3 years after it pays KHH the royalties due for such Products. Such auditors will not disclose to KHH or to any third party any information learned through such examination. However, if MOI challenges any finding of
underpayment, the auditors may disclose to KHH such information as is necessary to justify the auditors’ conclusions. KHH will not use any such information for any purpose other than determining and enforcing its rights under this Agreement. If
KHH’s examination of such records and books reveals any underpayment greater than 4% of the amount actually paid to KHH in the relevant time period, MOI will promptly pay to KHH the amount of such underpayment, and MOI will pay to KHH the
reasonable costs and expenses incurred by KHH in connection with such examination. 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

 ARTICLE 8 

TRANSFER AND DILIGENCE 

8.1    Transfer.  Within 60 days of the Effective Date, KHH will deliver to MOI the following:

 (a)    A separate tangible description of all KHH and BASF Technology Rights and copies of all related
contracts, including the method of manufacture and formulation of the Products except for “Assignee Information” as defined in the Agro Kanesho License Agreement. 

(b)    All original or scanned (electronic) original documents and correspondence related to the Registration
application filed by KHH with the United States Environmental Protection Agency with respect to technical registration of Reynoutria sachalinensis (REYSA)/Polygonum sachalinensis (POLSA), the Manufacturing Use Product, and the
formulated product Milsana® bioprotectant Concentrate (collectively, the “Registration Application”). 

(c)    All trademark and patent documents. 

(d)    Efficacy data. 

(e)    All documents relating to plant production, formulation experimentation and final formulas 

8.2    Consulting Services.   MOI will pay KHH $100.00 per hour of expert consulting services by
KHH personnel to facilitate the transfer under Section 8.1 and to otherwise assist MOI in the development of the Product; provided that MOI is not obligated to pay KHH more than a combined total of [*****], accumulated in 2007 and
2008 for such services, unless MOI requests more than [*****] hours of services, at which time the parties will mutually agree to a per hour price. The parties will mutually agree on the timing and scope of the services to be provided by KHH under
this Section. The fees for such consulting services will be due 30 days after MOI’s receipt of the related invoice, which must be accompanied by detailed description of the services. In addition, MOI will be responsible for reimbursing KHH for
all reasonable out-of-pocket, pre-approved expenses related to the provision of such services. The foregoing fee represents the entire amount MOI is obligated to pay to KHH for such services. 

8.3    Diligence.  MOI may perform a due diligence investigation relating to the Technology
Rights, the potential Products and the related business prospects (the “Diligence”). MOI’s start of diligence is when patents, trademarks, EPA registration documents and production information have been received. If within
sixty (60) days after receipt of this information, MOI determines that any aspect of the Technology Rights or the potential Products are not satisfactory, then MOI may terminate this Agreement upon 15 days’ notice to KHH. However, prior to
so terminating this Agreement MOI shall first engage in good faith negotiations with KHH to modify the terms of this Agreement in order to reasonably address such unsatisfactory matters. If MOI finds something in its due diligence that requires
termination, then MOI will be entitled to a fee refund of its initial [*****]. 

8.4    Assignment.  KHH hereby assigns to MOI all of KHH’s right title and interest in and to
the Registration Application provided that such rights, title and interest shall revert if this Agreement is terminated for any reason. 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

 ARTICLE 9 

PROPRIETARY RIGHTS 

9.1    Registrations; Improvements.  MOI is entitled to submit all regulatory filings in its name
and shall own all such filings and other registrations, including the Registrations. Any improvements to the Licensed Patent Rights or any other Technology Rights, whether patentable or not, made by MOI shall be the sole property of MOI. 

9.2    MOI Trademarks.  MOI will obtain and maintain trademarks for the Product as MOI sees fit at
MOI’s sole discretion and at its own expense. MOI will retain sole and exclusive ownership of such trademarks at all times. Nothing in this Agreement shall be construed as conferring on KHH the right to use in advertising, publicity or other
promotional activities any name, trademark or tradename of MOI or its products. 
 9.3    Publicity.  
MOI may publicize the relationship under this Agreement as provided in Section 15.9. 
 ARTICLE 10 

INFRINGEMENT BY THIRD PARTY 

10.1    Right to Defend.  As between KHH and MOI, MOI will at its expense, have the first right
but not the obligation to protect the Licensed Patent Rights and other Technology Rights from infringement and prosecute infringers. If KHH supplies MOI with evidence of infringement of Licensed Patent Rights or other Technology Rights, KHH may by
written notice request MOI to take steps to enforce such intellectual property rights. If KHH does so, and MOI does not, within 90 days of the receipt of such notice, either (a) cause the infringement to terminate, or (b) initiate and
continue a legal action against the infringer, KHH may, upon written notice to MOI, initiate an action against the infringer at KHH’s Notwithstanding the foregoing, MOI will have the right to sublicense any alleged infringer pursuant to
Article 5. 
 10.2    Declaratory Judgment.  If a declaratory judgment action or claim or
counterclaim alleging invalidity, unenforceability or noninfringement of any of the Licensed Patents or other Technology Rights is brought against KHH or MOI, MOI may elect to have sole control of the action, and if MOI so elects it will bear all
the costs of the action. 
 10.3    Cooperation in an Action.  If one party institutes or
carries on a legal action pursuant to Section 10.1 or 10.2, the other party will fully cooperate with and supply all assistance reasonably requested by the party instituting or carrying on such action, including, if requested by the
party instituting the action and necessary to pursue the action, joining in such action at the expense of the party requesting such joinder. A party instituting or carrying on such an action will keep the other party informed of the progress of such
action. Such other party will be entitled to be represented by counsel in connection with such action at its own expense. 

10.4    Allocation of Recovery and Expenses.   Any amounts paid to KHH or MOI by third parties as
the result of an action brought by either party pursuant to Section 10.1 or 10.2 (such as in satisfaction of a judgment or pursuant to a settlement), will first be applied to reimbursement of the unreimbursed expenses (including
attorneys’ fees and expert fees) incurred by each party. If this Agreement has not been terminated and the recovery is in the form of lost 

 revenues, then any remainder of the recovery after expenses shall be paid first to KHH as provided in Article 6.
If this Agreement has not been terminated and the recovery is in the nature of lost profits, then the parties will in good faith impute the amount of Net Revenues which would have generated such profits, and the amounts to be paid under Article 6
shall be paid to KHH with respect to such imputed Net Revenues, with the remainder in either case to be paid to MOI. 
 ARTICLE 11

 CONFIDENTIALITY 

11.1    Scope.  During the term of this Agreement and for 5 years thereafter, MOI and KHH agree:
(a) not to disclose to any third party, except as specifically allowed by this Agreement, any Confidential Information of the other party, and (b) to limit disclosure of Confidential Information within its own organization to individuals
whose duties justify the need to know such information and who are legally obligated to comply with the terms of this Agreement; provided, however, that nothing herein will limit disclosures by MOI in connection with MOI’s
exercise of its license rights as granted in Article 5, so long as the recipient is likewise bound by Confidentiality obligations at least as restrictive as Article 11. To the extent practical, Confidential Information will be
disclosed in tangible form and marked “Confidential.” Information disclosed in non-tangible form, such as orally or by visual inspection, will be considered confidential when the disclosing party confirms in writing the fact and general
nature of the disclosure within 1 month after it is made. 
 11.2    Exclusions.  The recipient
of Confidential Information will be under no obligation with respect to any information which: (a) at the time of disclosure is available to the public; (b) after disclosure becomes available to the public through no fault of the
recipient, provided that the obligation of the recipient will cease only after the date on which such information has become available to the public; (c) the recipient can demonstrate through tangible evidence was in its possession before
receipt from the disclosing party; (d) is disclosed to the recipient without restriction on disclosure by a third party who has the lawful right to disclose such information; or (e) was independently developed by the recipient as proven by
contemporaneous documentation made prior to the disclosure to recipient. Confidential Information will not be deemed to be within the foregoing exceptions merely because it is: (i) specific and embraced by more general information in the public
domain or the recipient’s possession or; (ii) a combination which can be pieced together to reconstruct the Confidential Information from multiple sources, none of which shows the whole combination, its principle of operation, or method of
use. 
 11.3    Required Disclosure.  It will not be a breach of this Article if the recipient
party is required to disclose the other party’s Confidential Information pursuant to an order of the government or a court of competent jurisdiction, provided that (a) the recipient party provides the other party with adequate
notice of the court or government order and the required disclosure, (b) the recipient party cooperates with the other party’s efforts to protect its Confidential Information with respect to such disclosure, and (c) the recipient
party takes all reasonable measures requested by the other party to challenge or to modify the scope of such required disclosure. 

 11.4    Terms of this Agreement.   Except as
expressly provided herein, MOI and KHH agree not to disclose any terms of this Agreement to any third party without the consent of the other party; provided, however, that disclosures may be made as required by securities or other
applicable laws, to actual or prospective investors and corporate partners, and to a party’s accountants, attorneys, and other professional advisors who agree to appropriate confidentiality provisions to protect such information from disclosure
or improper use, and by MOI to Sublicensees or potential Sublicensees. Also, nothing in this Agreement shall prevent MOI from providing to another customer MOI’s standard form agreements. 

ARTICLE 12 
 PATENTS AND
PATENT COSTS 
 12.1    Patent Costs.  Subject to the terms of Sections 12.2 and
13.3, from and after the Effective Date, MOI will pay for 100% of the patent costs incurred in connection with the Licensed Patent Rights, 

12.2    Responsible Party.  MOI will have the sole right to right to apply for, prosecute and
maintain, from the Effective Date through the termination of this Agreement, the Licensed Patent Rights and other Technology Rights. The application filings, prosecution, maintenance and payment of all fees and expenses, including legal fees,
relating to the Licensed Patent Rights will be the responsibility of MOI during such period, subject to Section 133. At MOI’s expense, KHH will provide MOI with all information necessary or useful for the filing and
prosecution of such Licensed Patent Rights and other Technology Rights and will cooperate fully with MOI so that MOI may establish and maintain such rights. Patent attorneys chosen by MOI will handle all patent filings and prosecutions, on behalf of
KHH, provided, however, KHH will be entitled to review and comment upon and approve, all material actions undertaken in the prosecution of all patents and applications. KHH will be deemed to have approved any such action if it fails to
disapprove such action within 10 business days of request for approval. KHH will promptly provide any comments or approvals which it elects to provide hereunder. If MOI declines to apply for, prosecute or maintain any Licensed Patent Rights and
other Technology Rights, KHH will have the right to pursue the same at KHH’s expense and MOI will have no rights under KHH’s interest therein nor any obligation to reimburse KHH for its related prosecution and maintenance fees. If MOI
decides not to apply for, prosecute or maintain any Licensed Patent Rights, MOI will give sufficient and timely notice to KHH so as to permit KHH to apply for, prosecute and maintain such Licensed Patent Rights. In such event, MOI will provide KHH
with all information necessary or useful for the filing and prosecution of such Licensed Patent Rights and will cooperate fully with KHH so that KHH may establish and maintain such rights. 

ARTICLE 13 
 TERM AND
TERMINATION 
 13.1    Term.  The term of this Agreement will commence on the Effective Date
and, unless earlier terminated in accordance with this Article, expire on the later of (a) the 10th anniversary of the Effective Date, or (b) the expiration of the last-to-expire issued
Valid Claim and any other patent issued relating to any other Technology Rights. 

 13.2    Termination by KHH.  KHH may terminate this
Agreement prior to the date it would otherwise expire pursuant to Section 13.1 if (a) MOI materially breaches this Agreement and fails to cure such breach within 60 days after notice from KHH of such breach, or (b) any
proceedings are instituted by or against MOI under any bankruptcy, insolvency, or moratorium law and such remain undismissed for at least 90 days. 

13.3    Termination by MOI.  MOI may terminate this Agreement prior to the date it would otherwise
expire pursuant to Section 13.1 if (a) KHH materially breaches this Agreement and fails to cure such breach within 60 days after notice from MOI of such breach, or (b) any proceedings are instituted by or against KHH under any
bankruptcy, insolvency, or moratorium law and such remain undismissed for at least 90 days. Also, MOI may terminate this Agreement as provided in Sections 8.3. 

13.4    Rights Regarding Products.  Notwithstanding anything herein to the contrary, following the
termination or expiration of the term of this Agreement, MOI will have the right to use or sell Products on hand on the date of such termination or expiration and to complete Products in the process of manufacture at the time of such termination or
expiration and use or sell the same, provided that MOI will submit the applicable royalty reports described in Sections 7.1, along with the royalty payments required above in accordance with Section 6.2 for Sale of such
Products. MOI may continue to sell Products to customers beyond the time period of the agreement. 

13.5    No Waiver of Claims; Assignment of Sublicenses.  Termination of this Agreement for any
reason will not release any either party from any liability which had accrued to the other party or which is attributable to a period prior to such termination. Upon any termination of this Agreement, KHH will accept an assignment by MOI of any
sublicenses granted by MOI to Sublicensees in accordance with Section 5.3, and any sublicense so assigned will remain in full force and effect 

13.6    Survival.  Termination of this Agreement will not relieve MOI of liability for payment of
any royalty due for Products made prior to the effective date of such termination. Also, Articles 2, 3, 4, 9, 11, 13, 14 and 15 will survive the expiration or termination of this Agreement for any reason. 

13.7    Return of Materials and Confidential Information. Upon termination of this Agreement for any reason, MOI
shall return to KHH all materials, Confidential Information, KHH Technology Rights and BASF Technology Rights, and MOI shall not use the same or any part thereof for any purpose whatsoever. 

13.8    Consequences of Termination. Subject to its rights under Sections 13.4, if applicable, if MOI terminates
this Agreement for any reason prior to 2016, it shall refrain, directly or indirectly, from the growing, production, marketing or distribution of Products anywhere within the Territory for two years after such termination, provided that MOI may
retain and continue to use such materials as necessary to exercise rights under Sections 13.4. 

 ARTICLE 14 

INDEMNITY 

14.1    MOI Indemnity.  MOI hereby agrees to defend, at its own expense, KHH from and against any
third party claim alleging, arising out of, or resulting from, (a) any breach of or inaccuracy in any representation or warranty made by MOI herein, or (b) the use or commercialization by MOI, its Sublicensees or assignees of the Licensed
Patent Rights or any other Technology Rights to the extent that any such claim arise solely from the actions of MOI. Subject to compliance with Section 14.3, MOI agrees to pay any damage or award finally awarded against KHH in such
action or agreed upon in settlement. 
 14.2    KHH Indemnity.  KHH agrees to defend MOI from
and against any third party claim alleging, arising out of, or resulting from, any breach of or inaccuracy in any representation or warranty made by KHH herein. Subject to compliance with Section 14.3, KHH agrees to pay any damage or award
finally awarded against MOI in such action or agreed upon in settlement. 

14.3    Process.  Any party obligated to provide indemnity under this Article must be
(a) notified promptly of any claims for which indemnity is sought and of which the applicable party has notice, (b) have the sole right to control and defend or settle any litigation within the scope of such party’s indemnity, and
(c) provided reasonable cooperation be the indemnified party in the defense of any such claims. 
 ARTICLE 15 

MISCELLANEOUS 

15.1    This Agreement will be governed by the laws of the State of California. 

15.2    Assignment.  This Agreement may not be assigned or otherwise transferred by any party
without the prior written consent of the other party; provided, however, that either party may assign this Agreement, without the consent of the other party (a) to any of its Affiliates, if the assigning party guarantees the full
performance of its Affiliate’s obligations hereunder, or (b) in connection with the transfer or sale of all or substantially all of the related assets or business or in the event of its merger or consolidation with another company. In all
cases the assigning party will provide the other party with prompt notice of any such assignment. No assignment will release a party from responsibility for the performance of any accrued obligation of such party hereunder. 

15.3    Notices.  All notices, requests or consents required or permitted under this Agreement
will be made in writing and will be given to the other party by personal delivery, registered or certified mail (with return receipt), overnight air courier (with receipt signature) or facsimile transmission (with “answerback” confirmation
of transmission), sent to such party’s address or telecopy numbers set forth below, or such other addresses or telecopy numbers of which the parties have given notice pursuant to this Section. Each such notice, request or consent will be deemed
effective upon the date of actual receipt, receipt signature or confirmation of transmission, as applicable. 
  

			
	If to MOI:	  	If to KHH:

			
	Marrone Organic Innovations, Inc.	  	KHH Biosci, Inc.
	215 Madson Place, Suites B/C	  	 [*****]

	Davis, CA 95618 USA	  	
	Attn: Dr. Pamela G. Marrone	  	
	Phone: (530) 750-2800	  	
	Facsimile: (530) 750-2808	  	

 15.4    Entire Agreement.   This Agreement constitutes the entire
agreement of the parties with respect to the subject matter herein and supersedes all prior agreements with respect thereto. This Agreement may be amended only in writing signed by both parties. 

15.5    Severability.  If a court or regulatory authority of competent jurisdiction determines
that one or more of the paragraphs or provisions of this Agreement are or may be invalid or unenforceable such decision will not affect the remainder of this Agreement. 

15.6    Force Majeure.  The parties will not be liable for any delay in or failure of
performance hereunder due to any contingency beyond its reasonable control including but not limited to an act of God, war, mobilization, insurrection, rebellion, civil commotion, riot, act of extremist or public enemy, sabotage, labor dispute,
lockout, strike, explosion, fire, flood, storm, accident, drought, equipment failure, power failure, shortage of cars, delay of carrier, embargo, law, ordinance, rule or regulation, whether valid or invalid, including priority requisition,
allocation, or price control. 
 15.7    Waiver.  Failure by either party hereto to exercise or
enforce any rights conferred upon it by this Agreement will not be deemed to be a waiver of any such rights or operate so as to bar the exercise or enforcement thereof or of any other rights at any subsequent time or times. 

15.8    Status of the Parties.  Nothing in this Agreement will be construed as to constitute a
partnership or joint venture between the parties or authorize either to represent the other party or contract any liability on behalf of the other party. 

15.9    Joint Press Release; Publicity.  Upon execution of this Agreement or as soon as
practicable thereafter, the parties will issue a joint press release, the text of which will be mutually acceptable to the parties. In addition, from time to time during the term hereof, MOI may issue press releases and other forms of publicity
referring to the Products and KHH’s role with respect thereto, such to be subject to the consent of KHH (such consent not to be unreasonably withheld or delayed). 

15.10    No Consequential Damages.  Except for claims arising out of breach of Article 11,
neither party will be liable to the other for any special, consequential, incidental, or indirect damages arising out of this agreement, however caused, under any theory of liability. 

15.11    Construction.  This Agreement is the result of negotiations among, and has been reviewed
by, KHH and MOI. Accordingly, this Agreement will be deemed to be the product of both parties, and no ambiguity will be construed in favor of, or against, KHH or MOI. 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

 15.12    Other Interpretive Provisions.  References
in this Agreement to “Articles” and “Sections” are to articles and sections herein unless otherwise indicated. The words “include” and “including” and words of similar import when used in this Agreement will
not be construed to be limiting or exclusive. Except as provided in a particular context, the word “or” when used in this Agreement may mean each as well as all alternatives. Headings in this Agreement are for convenience of reference only
and are not part of the substance hereof. This Agreement may be executed in two or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. 

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed on the dates
indicated below but to be effective as of the Effective Date. 
  

									
	MARRONEORGANIC INNOVATIONS, INC.	 		 	KHH BIOSCI, INC.
					
	By:	 	/s/ Pamela Marrone	 		 	By:	 	/s/ Hans von Amsberg
	Name:	 	Pamela Marrone	 		 	Name:	 	Hans von Amsberg
	Title:	 	President & CEO	 		 	Title:	 	President KHH BioSci, Inc.
	Date:	 	May 21, 2007	 		 	Date:	 	May 22, 2007

 EXHIBIT C 

LICENSED PATENTS 
  

							
	 Country
	  	 Number
	  	 Status
	  	 Expiring

	USA	  	5,989,429	  	Granted	  	[On or around 2016]
	USA	  	4,863,734	  	Granted	  	Sept. 05, 2006 [Expired]
	Canada	  	1,292,679	  	Granted	  	Dec. 03, 2008 [Not maintained]
	South Africa	  	0088/7962	  	Granted	  	Oct. 25, 2008 [Not maintained]
	Australia	  	746341	  	Granted	  	November 5, 2018

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00218-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00218-of-00352.parquet"}]]